Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

@article{Grob2011PilotSO,
  title={Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.},
  author={Charles S. Grob and Alicia Danforth and Gurpreet S Chopra and Marycie Hagerty and Charles McKay and Adam L. Halberstadt and George R. Greer},
  journal={Archives of general psychiatry},
  year={2011},
  volume={68 1},
  pages={
          71-8
        }
}
CONTEXT Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety. DESIGN A double-blind… 
The role of psychedelics in palliative care reconsidered: A case for psilocybin
TLDR
The findings that single-dose psilocybin can produce acute and sustained improvements in cancer-related anxiety and depression is perhaps the most important and novel finding of the two studies, and add to and extend the findings of a similarly designed trial in patients with terminal cancer.
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future
  • D. Nutt
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2016
TLDR
This special issue of the Journal of Psychopharmacology contains two landmark studies – the most rigorous controlled trials to date using the psychedelic drug psilocybin, the active ingredient of magic mushrooms, and they showed that a single psychedelic experience could produce profound and enduring mental health benefits.
Use of the Classic Hallucinogen Psilocybin for Treatment of Existential Distress Associated with Cancer
This chapter reviews the potential of a treatment approach that uses psilocybin, a novel psychoactive drug, to ameliorate the psychospiritual distress and demoralization that often accompany a
Psilocybin in end of life care: Implications for further research
TLDR
This issue of the Journal of Psychopharmacology contains two important randomized controlled studies on the use of psilocybin to treat mood and anxiety in carefully selected and supervised patients with later stage malignancies and its mystical or spiritual experiences were highly correlated with clinical response and mediated four out of six primary outcome measures.
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer
TLDR
Data from recent placebo-controlled, double-blind, cross-over clinical trials showing evidence that administration of single (or few) doses of LSD and psilocybin was associated with rapid and sustained reductions in depressive and anxiety symptoms in patients with end-stage cancer and other life-threatening diseases is reviewed.
Potential Therapeutic Effects of Psilocybin
Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within
Are psychedelics effective in treating anxiety associated with a lifethreatening disease
TLDR
Both pilot studies and the RCT included in this review indicate that LSD or psilocybin are an effective treatment for anxiety associated with a life-threatening disease.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
TLDR
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress
  • S. Ross
  • Medicine
    International review of psychiatry
  • 2018
TLDR
It is demonstrated that psychedelic-assisted treatment can produce rapid, robust, and sustained improvements in cancer-related psychological and existential distress.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
TLDR
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms in several subjects.
LSD-assisted psychotherapy in patients with terminal cancer.
TLDR
A clinical study exploring the potential of a complex psychotherapeutic program utilizing psychedelic compounds to alleviate the emotional and physical suffering of cancer patients found that there was a definite reduction of the narcotic medication.
Human hallucinogen research: guidelines for safety
TLDR
The unique history of human hallucinogens research is discussed, the risks of hallucinogen administration and safeguards for minimizing these risks are reviewed, and carefully conducted research may inform the treatment of psychiatric disorders, and may lead to advances in basic science.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study
TLDR
PY affects core dimensions of altered states of consciousness and physiological parameters in a dose-dependent manner and provided no cause for concern that PY is hazardous with respect to somatic health.
Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer.
TLDR
Depression and hopelessness are the strongest predictors of desire for hastened death in this population of terminally ill cancer patients and provide independent and unique contributions.
Psychiatric Research with Hallucinogens: What have we learned?
After a twenty-five year period of virtual prohibition, formal psychiatric research with hallucinogenic drugs has resumed. This article reviews the process by which hallucinogens came to be viewed as
The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval
TLDR
It is revealed that psilocybin also produces a decrease in PPI at short ISIs that is correlated with impaired attention and consistent with deficient PPI in schizophrenia.
Psychotherapeutic Interventions at the End of Life: A Focus on Meaning and Spirituality
TLDR
This article explores existential themes in terms of patients' awareness of death and search for meaning and practitioners' promotion of personal agency and responsibility as patients face life-and-death issues through Meaning-centred group therapy.
Psychiatry and Terminal Illness
  • H. Chochinov
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2000
TLDR
There is a small but emerging literature that can guide psychiatrists in their role of providing care to dying patients and psychiatry has an expanded and important role to play within the domain of palliative care.
...
1
2
3
4
5
...